PolyPid (NASDAQ:PYPD) Earns “Buy” Rating from HC Wainwright

PolyPid (NASDAQ:PYPD)‘s stock had its “buy” rating reaffirmed by equities research analysts at HC Wainwright in a research note issued on Monday,Benzinga reports. They currently have a $14.00 price target on the stock. HC Wainwright’s price objective would indicate a potential upside of 460.00% from the stock’s current price.

Separately, Craig Hallum began coverage on shares of PolyPid in a report on Monday, November 4th. They set a “buy” rating and a $10.00 price objective on the stock.

PolyPid Trading Up 2.9 %

Shares of PYPD stock opened at $2.50 on Monday. The firm has a 50-day moving average price of $3.30 and a 200 day moving average price of $3.57. PolyPid has a 12-month low of $2.37 and a 12-month high of $9.20. The company has a market capitalization of $11.99 million, a P/E ratio of -0.32 and a beta of 1.33. The company has a quick ratio of 1.00, a current ratio of 1.00 and a debt-to-equity ratio of 1.17.

Institutional Inflows and Outflows

An institutional investor recently raised its position in PolyPid stock. Rosalind Advisors Inc. increased its position in shares of PolyPid Ltd. (NASDAQ:PYPD) by 62.9% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 679,168 shares of the company’s stock after acquiring an additional 262,368 shares during the quarter. PolyPid comprises about 1.5% of Rosalind Advisors Inc.’s investment portfolio, making the stock its 18th largest position. Rosalind Advisors Inc. owned approximately 14.16% of PolyPid worth $2,336,000 at the end of the most recent reporting period. 26.47% of the stock is owned by hedge funds and other institutional investors.

About PolyPid

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions.